Home Cart 0 Sign in  
X

[ CAS No. 110-03-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 110-03-2
Chemical Structure| 110-03-2
Chemical Structure| 110-03-2
Structure of 110-03-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 110-03-2 ]

Related Doc. of [ 110-03-2 ]

Alternatived Products of [ 110-03-2 ]

Product Details of [ 110-03-2 ]

CAS No. :110-03-2 MDL No. :MFCD00004473
Formula : C8H18O2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZWNMRZQYWRLGMM-UHFFFAOYSA-N
M.W : 146.23 Pubchem ID :8031
Synonyms :

Calculated chemistry of [ 110-03-2 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 42.97
TPSA : 40.46 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.62 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.11
Log Po/w (XLOGP3) : 0.81
Log Po/w (WLOGP) : 1.31
Log Po/w (MLOGP) : 1.29
Log Po/w (SILICOS-IT) : 0.97
Consensus Log Po/w : 1.3

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.06
Solubility : 12.8 mg/ml ; 0.0873 mol/l
Class : Very soluble
Log S (Ali) : -1.24
Solubility : 8.39 mg/ml ; 0.0574 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.16
Solubility : 10.0 mg/ml ; 0.0685 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.54

Safety of [ 110-03-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 110-03-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 110-03-2 ]
  • Downstream synthetic route of [ 110-03-2 ]

[ 110-03-2 ] Synthesis Path-Upstream   1~23

  • 1
  • [ 110-03-2 ]
  • [ 54237-96-6 ]
  • [ 69814-56-8 ]
Reference: [1] Patent: US5455361, 1995, A,
  • 2
  • [ 110-03-2 ]
  • [ 6223-78-5 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In water 2,5-Dichloro-2,5-dimethylhexane (compound 2) was synthesized using a known procedure set forth in Bruson H et al., J Am Chem Soc, 62:36 (1940), whereby 50 g of 2,5-dimethylhexane-2,5-diol (compound 1 ) and 1 L of concentrated hydrochloric acid was used. Yield was measured quantitatively. Properties of compound 2 matched that reported in Bruson et al.
94% With nitrogen In dichloromethane 2,5-Dichloro-2,5-dimethylhexane
A 2L three neck round bottom flask fit with an overhead stirrer, thermometer, and nitrogen inlet was charged with 1.2L concentrated HCI. The HCI was stirred and chilled in an ice/salt bath to 0 °C.
Gradually, 150 g of 2,5-dimethyl-2,5-hexanediol (Aldrich) was added to the HCI.
The reaction mixture was initially a milky white slurry which gradually thickened and the ice bath was removed to allow the reaction to warm to 10 C.
The solids were isolated by filtration, dissolved in methylene chloride (500 mL) and washed repeatedly with water until neutral to pH paper.
The organics were dried over anhydrous magnesium sulfate and left in the refrigerator overnight.
The resulting mixture stripped on the rotary evaporator to yield)of white crystalline 2,5-dichloro-2,5-dimethylhexane (152 g, 94percent pure by GC).
1H-NMR (CDCl3, 500 MHz) δ 1.95 (s, 4H); 1.60 (s, 12H).
92% With hydrogenchloride In water at 20℃; for 4 h; 2, 5-Dimethyl-2, 5-hexanediol (200 grams, 1.37 mole) was added as a solid portion wise to 3 liters of concentrated hydrochloric acid in a large Erlenmeyer flask. The diol quickly dissolved in the hydrochloric acid and the desired product 2, 5-dichloro-2, 5-dimethythexane precipitated out of solution as it was formed. The reaction was stirred at room temperature for 4 hours. One liter of 50percent ethyl acetate in hexanes were added and the organic later separated and washed several times with water (until neutral by pH paper). The organic solvents were removed in vacuo at room temperature The crude 2, 5-dichloro-2, 5-dimethylhexane was dissolved in hexanes and plugged through a pad of silica gel (10:1 ratio) and eluted with hexanes. This final filtration step gives a white solid after removal of the organic solvent in vacuo. Recovery of pure 2,5-dichloro-2,5-dimethylhexane was 230 grams 92percent yield. 1H NMR (CDCl3, delta): 1.96 (4H, s); 1.61 (12H,s).
89% With hydrogenchloride In water for 1 h; Synthesis of 2,5-dichloro-2,5-dimethylhexane
The synthesis was accomplished as previously described [Mayr, H., et al., Chem. Ber. 124: 203, 1999].
2,5-Dimethyl-2,5-hexanediol (73.1 grams, 0.500 mol) was stirred with 37percent aqueous HCl (250 ml) for 1 hour.
The initially homogeneous mixture precipitated to yield a crystalline product.
The product was extracted with 600 ml of petroleum ether and dried with CaCl2.
Evaporation of the solvent yielded 81.9 grams (89percent) of an NMR-spectroscopically pure solid, which was recrystallized from petroleum ether (mp: 68-68.5° C.) as 2,5-dichloro-2,5-dimethylhexane.
87% With hydrogenchloride In water at 20℃; for 1 h; To 2,5-dimethyl-2,5-hexanediol (10 g, 68.5 mmol) in a 500 mL flask was added reagent grade concentrated HCl (150 mL) and the solution was stirred at ambient temperature for 1 h. Water (100 mL) and CH2Cl2 (100 mL) were then added slowly and the layers were separated. The aqueous layer was washed with additional CH2Cl2 (100 mL). The combined organic layers were dried over MgSO4 and filtered thru silica gel pad. The solvent was removed to yield 10.9g (87percent) of 2,5-dichloro-2,5-dimethylhexane. The dichloride was dissolved in 150 mL Of CH2Cl2 and 9.6 mL of toluene (90 mmol) was added. AlCl3 (390 mg, 2.9 mol) was added in portions over 5 min at ambient temperature. HCl is evolved and the solution turns dark red. The reaction was placed in an ice-bath and quenched with deionized water (120 mL). Hexane (150 mL) was added and the organic layer was removed. The aqueous layer was washed with additional hexane (150 mL). The combined organic layers were washed with water (200 mL) and brine (100 mL) and dried over MgSO4. The solvent was removed in vacuo to give l,l,4,4,6-pentamethyl-l,2,3,4- tetrahydronaphthalene as a colorless oil that crystallized after storage at -2O0C.[0155] Yield: 12 g (91percent); low melting white solid; Rf = 0.7 in 100percent hexane.[0156] 1H-NMR (CDCl3, 300 MHz) δ 1.32 (s, 12H), 1.7 (s, 4H), 2.34 (s, 3H), 6.85 (dd, IH), 7.14 (d, IH), 7.22 (d, IH)[0157] 13C-NMR (CDCl3, 75 MHz) δ 21.54, 32.26, 32.32, 34.29, 34.51, 35.57, 35.63, 126.64, 126.75, 127.21, 134.93, 142.00, 144.83.
86.7% With hydrogenchloride In water at 20℃; for 0.5 h; 2, 5-Dimethyl 2, 5-hexanediol (21) (7.31 g) was added to concentrated hydrochloric acid (100 mL) and stirred vigorously at room temperature for 30 minutes. The obtained precipitate was collected by filtration, washed with water, and dissolved in dichloromethane. After washing with water and saturated brine, the organic layer was dried with anhydrous sodium sulfate. Filtration and concentration under reduced pressure gave the title compound (22) (7.93 g, yield 86.7percent) as a white solid.
85% With hydrogenchloride In water at 20℃; for 1.5 h; Concentrated HCl (1.2 L, 14.4 mol) was added to commercial 2,5-dimethyl-hexane-2,5-diol (202 g, 1.4 mol) and the slurry was stirred at ambient temperature for 1.5 h..
The mixture was filtered..
The filter cake was washed with water (*3), dissolved in Et2O, washed successively with H2O, NaHCO3, and brine, dried over Na2SO4, and concentrated in vacuo.. Recrystallization of the resulting solid from Et2O gave the title compound as white crystals (216 g, 85percent). 1H NMR (300 MHz, CDCl3): δ1.60 (s, 12H), 1.95 (s, 4H).
85% With hydrogenchloride In water at 20℃; for 1.5 h; Concentrated HCl (1.2 L, 14.4 mol) was added to commercial 2,5-dimethyl-hexane-2,5-diol (202 g, 1.4 mol) and the slurry was stirred at ambient temperature for 1.5 h. The mixture was filtered. The collected solid was washed with water (.x.3), dissolved in Et2O, washed successively with H2O, NaHCO3, and brine, dried over Na2SO4, and concentrated in vacuo. Recrystallization of the resulting solid residue from Et2O gave the title compound as white crystals (216 g, 85percent). 1H NMR (300 MHz, CDCl3): δ 1.60 (s, 12H), 1.95 (s, 4H).
85% With hydrogenchloride In water at 20℃; Inert atmosphere A solution of 2,5-dimethyl-2,5-hexanediol 19(2.0 mmol) in 37percent hydrochloric acid (42 mmol) was stirredat room temperature for 65 h. The mixture was extractedwith ethyl acetate and the organic phase was washed with5percent NaHCO3 and dried over anhydrous MgSO4. The solventwas removed under reduced pressure. The product waspurified by flash chromatography and recrystallizationusing hexane as solvent, which furnished 2,5-dichloro-2,5-dimethyl hexane 20 as white crystals in 85percent yield.mp 68 °C; 1H NMR (300 MHz, CDCl3) δ 1.58 (s, 12H,3CH3), 1.93 (s, 4H, 2CH2); 13C NMR (75 MHz, CDCl3) δ 32.52, 41.14, 70.35.
81% With hydrogenchloride In water for 0.25 h; 2,5-dimethyl-hexane-2,5-diol (10 g, 68.4 mmol) was placed in a reaction vessel with gentle stirring. Cone. HCI (aq, 80 mL) was added and the resulting mixture was stirred slowly for 15 mins. The resulting suspension was left standing for 2 h. It was then filtered and washed with 2x30 mL of water. A resulting solid was dried under high vacuum to afford the title compound T-1 (10.1 g, 81percent yield). The analytical data matches those reported in the literature.
79.91% With hydrogenchloride In water at 0 - 20℃; for 12 h; 2, 5-Dichloro-2, 5-dimethylhexane
To a two-neck 250 mL RB flask charged with 2, 5-dimethyl-2, 5-hexanediol (15 g, 102.6 mmol), conc. HCl (60 mL) was added slowly at 0° C., and stirred at RT overnight.
The reaction mixture was quenched with ice, obtained heterogeneous mixture was filtered and washed with water and dried under vacuum to yield a title compound as a white solid (15.0 g, yield: 79.91percent): 1H NMR (300 MHz, CDCl3): 1.88 (s, 4H), 1.53 (s, 12H).
73% With thionyl chloride In dichloromethane at 20℃; for 4 h; Thionyl chloride (25 ml, 341.8 mmol) is added at ambient temperature to a solution of 2, 5-DIMETHYL-2, 5-HEXANEDIOL (20.0 g, 136.8 mmol) in 250 ml OF DICHLOROMETHANE. The reaction mixture is stirred for 4 hours. Then 250 ml of distilled water is added. The organic phase is separated and washed with 10percent NAHCO3 solution (2X250 ml), then dried over MGS04 and evaporated to dryness to give the title compound (18.37 g, 73percent). APOS;H NMR (CDCI3) : 1.57 (s, 12H, CH3) ; 1.92 (s, 4H, CH2).
73% With thionyl chloride; sodium hydrogencarbonate In dichloromethane; water a)
Preparation of 2,5-dichloro-2,5-dimethylhexane
Thionyl chloride (25 ml, 341.8 mmol) is added at ambient temperature to a solution of 2,5-dimethyl-2,5-hexanediol (20.0 g, 136.8 mmol) in 250 ml of dichloromethane.
The reaction mixture yellows and the agitation is continued for 4 hours.
The progress of the reaction is controlled by thin film chromatography (eluent ether: petroleum ether=50:50).
At the end of reaction, 250 ml of distilled water is added, it is decanted and the organic phase is neutralised using 2*250 ml of a 10percent NaHCO3 solution.
The product is dried with MgSO4 filtered and evaporated to dryness. 18.37 g of a solid 2,5-dichloro-2,5-dimethylhexane is obtained (gross yield=73percent).
NMR1H 200 MHz (CDCl3): 1.57 (s, 12H, Me); 1.92 (s, 4H, -CH2-).
73% With hydrogenchloride In water For comparison in the biological evaluation (Fig. 1 and 2) of compounds 1 - 3, [8 and 9] and 30-32, [8b and 9b] an authentic sample of bexarotene and its ketone analog (33a) were synthesized, following the reported route (Boehm, et al. "Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids." J. Med. Chem. 1994, 37, 2930-2941 ): a seven step, convergent synthesis that gave a 29percent overall yield of bexarotene. The first sequence of steps to bexarotene concerned the SN1 conversion of 2,5-dimethyl-2,5-hexanediol (33b) to 2,5-dichloro-2,5- dimthylhexane (34) by HCI, and the subsequent aluminum trichloride catalyzed Friedel-Crafts alkylation of toluene to give 1 ,2,3,4-tetrahydro-l .l A4,6-pentamethylnapthalene (35) in 68percent yield over two steps (Scheme 1 ).
70% With hydrogenchloride In water at 20℃; for 16 h; 2,5-dimethylhexane-2,5-diol (10.0 g, 68.4 mmol) was stirred in 50 mL of conc. aq. HCl for 16 hr. The reaction was diluted with 50 mL of H2O and extracted with Et2O (3×50 mL). The combined organics were evaporated to 30 mL. A white crystalline solid precipitated and was collected via filtration (8.8 g, 70percent) and was not purified further. 1H NMR (400 MHz, CDCl3): δ = 1.96 (s, 4H), 1.61 (s, 12H). 1H NMR matches literature.5 2,5-dichloro-2,5-dimethylhexane (5.50 g, 30.0 mmol) and o-bromotoluene (10.3 g, 60.0 mmol) were dissolved in 60 mL of DCM. AlCl3 (400 mg, 3.00 mmol) was added slowly over 5 minutes. The reaction was stirred for 1 hr under an Ar atmosphere. 50 mL of H2O was added to the reaction and the layers were separated. The aqueous was extract with hexane (3×50 mL). The combined organics were dried with MgSO4, filtered, and removed under vacuum to yield an oil. The oil was dissolved in 75 mL of boiling MeOH and then cooled in an ice bath. The mixture was filtered to yield white crystals (6.6 g, 78percent). 1H NMR (400 MHz, CDCl3): δ = 7.43 (s, 1H), 7.15 (s, 1H), 2.35 (s, 3H), 1.66 (s, 4H), 1.26 (s, 12H). 1H NMR matches literature[5].
68% at 20℃; for 2 h; Concentrated HCl (400 mL) was added to 2,5-dimethyl-2,5-hexanediol (50.0 g, 432 mmol) dropwise with gentle swirling. The diol flakes gradually dissolved and a white precipitate formed simultaneously. The reaction mixture was stirred at room temperature (RT) for 2h; the white precipitate was filtered off and was washed with water until pH ∼7 followed by cold EtOH. The solid was dried under vacuum to afford 1 as a white solid (42.5g, 68percent), mp 63–65 C (lit.2 63–65.8 C, lit.19 63–65°C). 1H NMR (CDCl3): δ 1.95 (s, 4H), 1.60 (s, 12H).
68% With hydrogenchloride In water at 20℃; (b) 2,5-Dichloro-2,5-dimethylhexane (1): Concentrated HCl (400 mL) was addedto 2,5-dimethyl-2,5-hexanediol (50.0 g, 432 mmol) dropwise with gentleswirling. The diol flakes gradually dissolved and a white precipitate formedsimultaneously. The reaction mixture was stirred at room temperature (RT) for2 h; the white precipitate was filtered off and was washed with water until pH7 followed by cold EtOH. The solid was dried under vacuum to afford 1 as awhite solid (42.5 g, 68percent), mp 63–65 C (lit.2 63–65.8 C, lit.19 63–65 C). 1H NMR(CDCl3): d 1.95 (s, 4H), 1.60 (s, 12H).
65% With hydrogenchloride In ethanol Example 11:
Preparation of (E)-methyl-4-[2-(3-bromomethyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoate
HCl gas was added by bubbling through a gas dispersion tube to a solution of 100 g (684 mmol) of 2,5-dimethyl-2,5-hexanediol in 300 mL of ethanol.
The reaction mixture slowly warmed from room temperature to 60° C. over 3 hours.
The reaction mixture was cooled in a wet ice bath and a white solid was filtered off.
The solid was washed with water and cold ethanol, then dried to give 65.2 g (65percent) of 2,5-dichloro-2,5-dimethylhexane (M+=181).

Reference: [1] Patent: WO2007/5568, 2007, A1, . Location in patent: Page/Page column 10
[2] Organometallics, 2012, vol. 31, # 21, p. 7579 - 7585
[3] Chinese Journal of Chemistry, 2010, vol. 28, # 10, p. 1951 - 1956
[4] Organic and Biomolecular Chemistry, 2018, vol. 16, # 35, p. 6586 - 6599
[5] Patent: EP1157047, 2003, B1,
[6] Patent: EP1105120, 2005, B1, . Location in patent: Page/Page column 13
[7] Recueil des Travaux Chimiques des Pays-Bas, 1988, vol. 107, p. 529 - 535
[8] Heterocycles, 2007, vol. 71, # 3, p. 557 - 567
[9] Tetrahedron Letters, 2012, vol. 53, # 39, p. 5302 - 5305
[10] Chemische Berichte, 1991, vol. 124, # 1, p. 203 - 206
[11] Journal of the American Chemical Society, 2004, vol. 126, # 51, p. 16716 - 16717
[12] Patent: US2016/97037, 2016, A1, . Location in patent: Paragraph 0513
[13] Organic Letters, 2012, vol. 14, # 18, p. 4866 - 4869
[14] Patent: WO2007/22437, 2007, A2, . Location in patent: Page/Page column 52
[15] Patent: JP2017/71567, 2017, A, . Location in patent: Paragraph 0183-0185
[16] Patent: US6759547, 2004, B1, . Location in patent: Page column 12
[17] Patent: US2004/198825, 2004, A1, . Location in patent: Page 5
[18] Journal of the Brazilian Chemical Society, 2018, vol. 29, # 1, p. 109 - 124
[19] Patent: WO2018/107289, 2018, A1, . Location in patent: Page/Page column 16
[20] Patent: US2016/333004, 2016, A1, . Location in patent: Paragraph 0314; 0317
[21] Patent: WO2004/48338, 2004, A1, . Location in patent: Page 13
[22] Patent: US6265423, 2001, B1,
[23] Journal of Medicinal Chemistry, 2009, vol. 52, # 19, p. 5950 - 5966
[24] Patent: WO2011/103321, 2011, A1, . Location in patent: Page/Page column 18-19
[25] ChemMedChem, 2012, vol. 7, # 9, p. 1551 - 1566
[26] Chemistry - A European Journal, 2013, vol. 19, # 10, p. 3504 - 3511
[27] Tetrahedron Letters, 2017, vol. 58, # 50, p. 4703 - 4708
[28] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1742 - 1747
[29] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 24, # 7, p. 1742 - 1747
[30] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[31] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
[32] Journal of the American Chemical Society, 1948, vol. 70, p. 479
[33] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1906, vol. 143, p. 496
[34] Helvetica Chimica Acta, 1924, vol. 7, p. 385
[35] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
[36] Journal of the American Chemical Society, 1973, vol. 95, p. 7449 - 7457
[37] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[38] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[39] Patent: US2004/10033, 2004, A1, . Location in patent: Page/Page column 11
[40] Patent: US2002/82265, 2002, A1,
[41] Patent: US5344959, 1994, A,
[42] Patent: US5475022, 1995, A,
[43] Patent: US5043482, 1991, A,
[44] Patent: US5149705, 1992, A,
[45] Patent: US5130335, 1992, A,
[46] Patent: US5214202, 1993, A,
[47] Patent: WO2003/106446, 2003, A1, . Location in patent: Page 19-20
[48] Patent: US8293803, 2012, B2,
[49] European Journal of Medicinal Chemistry, 2012, vol. 58, p. 346 - 354
[50] Medicinal Chemistry, 2014, vol. 10, # 4, p. 361 - 375
[51] Patent: CN103030646, 2016, B, . Location in patent: Paragraph 0352; 0355-0358
[52] Letters in Drug Design and Discovery, 2016, vol. 13, # 8, p. 729 - 733
[53] Breast Cancer, 2017, vol. 24, # 2, p. 299 - 311
[54] Dalton Transactions, 2018, vol. 47, # 9, p. 3128 - 3143
[55] Patent: US2018/207156, 2018, A1, . Location in patent: Paragraph 0195
  • 3
  • [ 110-03-2 ]
  • [ 75-36-5 ]
  • [ 6223-78-5 ]
Reference: [1] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1906, vol. 143, p. 496
  • 4
  • [ 7647-01-0 ]
  • [ 110-03-2 ]
  • [ 6223-78-5 ]
Reference: [1] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1906, vol. 143, p. 496
  • 5
  • [ 110-03-2 ]
  • [ 6683-46-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[2] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
[3] European Journal of Medicinal Chemistry, 2012, vol. 58, p. 346 - 354
[4] Letters in Drug Design and Discovery, 2016, vol. 13, # 8, p. 729 - 733
[5] Journal of the Brazilian Chemical Society, 2018, vol. 29, # 1, p. 109 - 124
[6] Patent: WO2018/107289, 2018, A1,
[7] Patent: US2018/207156, 2018, A1,
  • 6
  • [ 110-03-2 ]
  • [ 71-43-2 ]
  • [ 6683-46-1 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1997, vol. 39, # 6, p. 501 - 507
  • 7
  • [ 7446-70-0 ]
  • [ 110-03-2 ]
  • [ 71-43-2 ]
  • [ 6683-46-1 ]
  • [ 22306-30-5 ]
Reference: [1] Doklady Akademii Nauk SSSR, 1951, vol. 80, p. 369,371[2] Chem.Abstr., 1952, p. 5022
  • 8
  • [ 110-03-2 ]
  • [ 71441-28-6 ]
Reference: [1] Tetrahedron Letters, 2012, vol. 53, # 39, p. 5302 - 5305
  • 9
  • [ 110-03-2 ]
  • [ 22306-30-5 ]
Reference: [1] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
  • 10
  • [ 7446-70-0 ]
  • [ 110-03-2 ]
  • [ 71-43-2 ]
  • [ 6683-46-1 ]
  • [ 22306-30-5 ]
Reference: [1] Doklady Akademii Nauk SSSR, 1951, vol. 80, p. 369,371[2] Chem.Abstr., 1952, p. 5022
  • 11
  • [ 110-03-2 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[3] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[4] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
[5] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
[6] Patent: WO2011/103321, 2011, A1,
[7] Patent: US8293803, 2012, B2,
[8] ChemMedChem, 2012, vol. 7, # 9, p. 1551 - 1566
[9] Organic Letters, 2012, vol. 14, # 18, p. 4866 - 4869
[10] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1742 - 1747
[11] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 24, # 7, p. 1742 - 1747
[12] Patent: WO2018/107289, 2018, A1,
  • 12
  • [ 110-03-2 ]
  • [ 92050-16-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[2] Letters in Drug Design and Discovery, 2016, vol. 13, # 8, p. 729 - 733
[3] Patent: JP2017/71567, 2017, A,
[4] Journal of the Brazilian Chemical Society, 2018, vol. 29, # 1, p. 109 - 124
  • 13
  • [ 110-03-2 ]
  • [ 94497-51-5 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[2] Letters in Drug Design and Discovery, 2016, vol. 13, # 8, p. 729 - 733
  • 14
  • [ 110-03-2 ]
  • [ 27452-17-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[2] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[3] Tetrahedron Letters, 2012, vol. 53, # 39, p. 5302 - 5305
[4] Patent: US2016/97037, 2016, A1,
[5] Patent: CN103030646, 2016, B,
[6] Journal of the Brazilian Chemical Society, 2018, vol. 29, # 1, p. 109 - 124
[7] Patent: WO2018/107289, 2018, A1,
  • 15
  • [ 110-03-2 ]
  • [ 86-73-7 ]
  • [ 77308-48-6 ]
YieldReaction ConditionsOperation in experiment
53%
Stage #1: With aluminum (III) chloride In dichloromethane at -8 - 20℃; for 22.1667 h;
Stage #2: With sodium hydrogencarbonate In water
(i)
Synthesis of octamethyloctahydrodibenzofluorene
Into a 500 ml three-necked flask thoroughly purged with nitrogen, equipped with a three-way cock, a dropping funnel and a magnetic stirrer, were introduced fluorene 9.72 g (58.6 mmol) and 2,5-dimethyl-2,5-hexanediol 19.61 g (134 mmol) at room temperature.
Dehydrated dichloromethane 85 ml was further added, and the contents were stirred by the magnetic stirrer and cooled to -8°C in an ice bath.
Ground anhydrous aluminum chloride 38.9 g (292 mmol) was added to the mixture over a period of 70 minutes, and stirring was conducted for 2 hours at 0°C and further for 19 hours at room temperature outside the ice bath.
Then the resulting solution was quenched by being poured into ice water 150 ml.
Soluble matters were extracted with diethyl ether 500 ml, and an organic phase was neutralized with a saturated aqueous solution of sodium hydrogencarbonate and then washed with water.
The fractionated organic phase was dried over anhydrous magnesium sulfate.
After the magnesium sulfate was filtered off, the solvent of the filtrate was distilled away under reduced pressure.
The residue was washed six times with n-hexane 10 ml through a Kiriyama funnel and dried under reduced pressure to give white powder (12.0 g, 53 percent yield).
1H NMR spectrum (270 MHz, CDCl3): δ/ppm 1.3 (s, 12H), 1.4 (s, 12H), 1.7 (s, 8H), 3.8 (s, 2H), 7.4 (s, 2H), 7.6 (s, 2H) FD-MS spectrum: M/z 386 (M+)
Reference: [1] Patent: EP1548018, 2005, A1, . Location in patent: Page/Page column 28
  • 16
  • [ 110-03-2 ]
  • [ 77308-48-6 ]
Reference: [1] Journal of the American Chemical Society, 2004, vol. 126, # 51, p. 16716 - 16717
  • 17
  • [ 110-03-2 ]
  • [ 86-73-7 ]
  • [ 77308-47-5 ]
  • [ 77308-48-6 ]
Reference: [1] Bulletin de la Societe Chimique de France, 1980, vol. 2, # 7-8, p. 334 - 344
  • 18
  • [ 110-03-2 ]
  • [ 119999-22-3 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Patent: US8293803, 2012, B2,
[3] Chemistry - A European Journal, 2013, vol. 19, # 10, p. 3504 - 3511
[4] Tetrahedron Letters, 2017, vol. 58, # 50, p. 4703 - 4708
  • 19
  • [ 110-03-2 ]
  • [ 116233-17-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[2] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
  • 20
  • [ 110-03-2 ]
  • [ 153559-49-0 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[3] Patent: WO2011/103321, 2011, A1,
[4] Chemistry - A European Journal, 2013, vol. 19, # 10, p. 3504 - 3511
  • 21
  • [ 110-03-2 ]
  • [ 153559-46-7 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[3] Patent: WO2011/103321, 2011, A1,
  • 22
  • [ 110-03-2 ]
  • [ 153559-48-9 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[3] Patent: WO2011/103321, 2011, A1,
  • 23
  • [ 110-03-2 ]
  • [ 169126-64-1 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
Same Skeleton Products
Historical Records